title: Synthesis of conjugated chitosan and its effect on drug permeation from transdermal patches.
abstract: The aim of this study was to synthesis the conjugated chitosan by covalent attachment of thiol moieties to the cationic polymer, mediated by a carbodiimide to improve permeation properties of chitosan. Thioglycolic acid was covalently attached to chitosan by the formation of amide bonds between the primary amino groups of the polymer and the carboxylic acid groups of thioglycolic acid. Hence, these polymers are called as thiomers or thiolated polymers. Conjugation of chitosan was confirmed by Fourier transform-infrared and differential scanning calorimetric analysis. Matrix type transdermal patches of carvedilol were prepared using the different proportions of chitosan and chitosan-thioglycolic acid conjugates (2:0, 1.7:0.3, 1.4:0.6, 1:1, 0.6:1.4 and 0.3:1.7) by solvent casting technique. Prepared matrix type patches were evaluated for their physicochemical characterization followed by in vitro evaluation. Selected formulations were subjected for their ex vivo studies on Wistar albino rat skin and human cadaver skin using the modified Franz diffusion cell. As the proportion of conjugated chitosan increased, the transdermal patches showed increased drug permeation. The mechanism of drug release was found to be nonFickian profiles. The present study concludes that the transdermal patches of carvedilol using conjugated chitosan with different proportions of chitosan were successfully developed to provide improved drug permeation. The transdermal patches can be a good approach to improve drug bioavailability by bypassing the extensive hepatic first-pass metabolism of the drug.
authors.affiliation: Department of Pharmaceutics, Government College of Pharmacy, #2 P Kalinga Rao Road, Bangalore-560 027, India.
authors.forename: B K
authors.initials: BK
authors.lastname: Satheeshababu
authors.forename: K L
authors.initials: KL
authors.lastname: Shivakumar
keywords: Carvedilol; chitosan-thioglycolic acid conjugates; matrix monolithic system; transdermal drug delivery system
references.citation: Int J Pharm. 2003 Apr 30;256(1-2):183-9
references.pmid: 12695025
references.citation: Acta Pharm. 2007 Jun;57(2):151-9
references.pmid: 17507312
references.citation: Int J Pharm. 2000 Jan 25;194(2):239-47
references.pmid: 10692648
references.citation: Biomaterials. 2001 Sep;22(17):2345-52
references.pmid: 11511031
references.citation: Indian J Pharm Sci. 2008 Jul-Aug;70(4):455-60
references.pmid: 20046770
references.citation: Eur J Pharm Biopharm. 2007 Jun;66(3):422-8
references.pmid: 17196804
references.citation: Int J Pharm. 2001 Feb 1;213(1-2):193-8
references.pmid: 11165107
references.citation: Curr Drug Deliv. 2008 Oct;5(4):290-8
references.pmid: 18855598
references.citation: AAPS PharmSciTech. 2007 Jan 19;8(1):2
references.pmid: 17408218
references.citation: Vasc Health Risk Manag. 2008;4(1):23-30
references.pmid: 18629377